Header image

Session O: Oral Abstracts

Tracks
.
Friday, September 8, 2017
1:00 PM - 2:00 PM
Manhattan Ballroom

Speaker

Attendee325

Restrictions for Reimbursement of Interferon-Free Direct Acting Antiviral Therapies for HCV Infection in Europe

1:00 PM - 1:15 PM

Abstract

Speaker Presentation

Video Presentation

Biography

Attendee309

Safety And Efficacy Of Glecaprevir/Pibrentasvir In Patients With Chronic Hepatitis C Genotypes 1–6 Receiving Opioid Substitution Therapy

1:15 PM - 1:30 PM

Abstract

Speaker Presentation

Video Presentation

Biography

Attendee873

Paritaprevir/Ritonavir/Ombitasvir, Dasabuvir + Ribavirin In People With HCV Genotype 1 And Recent Injecting Drug Use Or Receiving OST: D3FEAT Study

1:30 PM - 1:45 PM

Abstract

Speaker Presentation

Video Presentation

Biography

Attendee796

Barriers to Hepatitis C Treatment Access Across the United States: Perspectives of Public Health Officials and Advocates

1:45 PM - 1:50 PM

Abstract

Speaker Presentation

Video Presentation

Biography

Attendee405

HCV Reinfection Following Successful Direct-Acting Antiviral Treatment among People who Inject Drugs: Preliminary Results from a Low-Threshold Treatment Setting

1:50 PM - 1:55 PM

Abstract

Speaker Presentation

Video Presentation

Biography

Attendee309

HCV Reinfection and Injection Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opioid Agonist Therapy: Co-Star Three-Year Follow-Up Study

1:55 PM - 2:00 PM

Abstract

Speaker Presentation

Video Presentation

Biography

Footer image
loading